Myron Cohen, MD, the Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology, co-led a global randomized, controlled and double-blinded study that shows the drug cabotegravir lowered HIV incidence among cisgender men and transgender women who have sex with men.
An announcement about the study was published in the UNC Health and UNC School of Medicine Newsroom.
Cohen, who is the director of the Institute for Global Health & Infectious Diseases and associate vice chancellor for Global Health and Medical Affairs, was interviewed by Science Magazine and recognized that the addition of long-acting cabotegravir as PrEP provides a powerful new HIV prevention weapon.
“This agent really could contribute to the goal of ending AIDS by 2030,” Cohen said.
Read the article here.